Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet's disease with infliximab

Iwata, Daiju; Namba, Kenichi; Mizuuchi, Kazuomi; Kitaichi, Nobuyoshi; Kase, Satoru; Takemoto, Yuko; Ohno, Shigeaki; Ishida, Susumu

Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet's disease with infliximab

Iwata, Daiju; Namba, Kenichi; Mizuuchi, Kazuomi et al.

Graefe's Archive for Clinical and Experimental Ophthalmology, 2012, 250(7), 1081-1087

Permalink : https://hdl.handle.net/2115/52973

このアイテムのアクセス数:1,409件（2026-10-06 10:04 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
GACEO250-7_1081-1087	pdf	389 KB	1,435

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/52973
タイトル	Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet's disease with infliximab
著者	Iwata, Daiju ; Namba, Kenichi ; Mizuuchi, Kazuomi ; Kitaichi, Nobuyoshi ; Kase, Satoru ; Takemoto, Yuko ; Ohno, Shigeaki ; Ishida, Susumu
e-Rad_Researcher 70374402 著者名 Iwata, Daiju
e-Rad_Researcher 70333599 著者名 Namba, Kenichi
e-Rad_Researcher 80598780 著者名 Mizuuchi, Kazuomi
e-Rad_Researcher 40431366 著者名 Kitaichi, Nobuyoshi
e-Rad_Researcher 60374394 著者名 Kase, Satoru
e-Rad_Researcher 20443939 著者名 Takemoto, Yuko
e-Rad_Researcher 50002382 著者名 Ohno, Shigeaki
e-Rad_Researcher 10245558 著者名 Ishida, Susumu
言語	英語
キーワード	Behçet's disease
	Retinal vasculitis
	Uveitis
	Antinuclear antibody
	Infliximab
	Biomarker
	Anti-TNF-α monoclonal antibody
発行日	2012-07
出版者	Springer Berlin / Heidelberg
収録物名	Graefe's Archive for Clinical and Experimental Ophthalmology
巻(号)	250(7)
ページ	1081-1087
抄録	Background: Infliximab, an anti-TNF-α monoclonal antibody, administered to Behçet's disease (BD) patients in Japan with refractory intraocular inflammation, has shown excellent clinical results. However, some patients demonstrate a decreased response to infliximab during the course of the treatment. In the present study, we investigated the correlation between this reduced therapeutic effect and elevation of the serum antinuclear antibody (ANA) titers in patients with BD who were undergoing infliximab therapy. Methods: Seventeen patients (14 males and 3 females) with uveitis in BD who were undergoing treatment with infliximab for 2 years or longer were enrolled. Their blood test results and clinical histories were obtained from medical records. Results: One patient (5.9%) was ANA-positive prior to the initiation of infliximab, and 11 patients (64.7%) developed positive ANA during the therapy. The appearance of ANA was observed 6 months after the initiation of the infliximab therapy, and its titres gradually increased. None of the patients showed lupus symptoms. Five patients (29.4%) have suffered from ocular inflammatory attacks since 6th month from the initiation of infliximab treatment and all of them were ANA-positive. In contrast, 4 patients (23.5%) who were ANA-negative experienced no ocular attacks during the follow-up period. Conclusions: Here we report the positive conversion and subsequent elevation of serum ANA titres in some patients with BD after the initiation of infliximab therapy. Since all recurrences of uveitis were shown only in the ANA-positive patients, serum ANA titre may be a helpful biomarker for predicting the recurrence of ocular attacks in BD patients treated with anti-TNF-α antibody therapies.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	The original publication is available at www.springerlink.com
PISSN	0721-832X
関連情報	PMID 22234352
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1007/s00417-011-1908-1